Pathogenesis of diabetic retinopathy;Patogeneze diabetické retinopatie

Vnitrni Lekarstvi

Volumn 53, Issue 5, 2007, Pages 498-505

  Pelikánová, Terezie ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Advanced glycation end products; Diabetic retinopathy; Hexosamine; Hyperglycemia; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BLOOD CLOTTING FACTOR; CELL ADHESION MOLECULE; GROWTH FACTOR; HEXOSAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; POLYOL; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; VASOACTIVE AGENT;

ANGIOGENESIS; APOPTOSIS; BASEMENT MEMBRANE; BLINDNESS; BLOOD FLOW; BLOOD VESSEL INJURY; CAPILLARY PERMEABILITY; CELL ACTIVATION; CELL HYPERPLASIA; CELL INFILTRATION; CELL PROLIFERATION; CONFERENCE PAPER; DIABETIC RETINOPATHY; DISEASE SEVERITY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GLIA; GLUCOSE METABOLISM; GRANULOCYTE; HEMODYNAMICS; HEREDITY; HUMAN; HYPERGLYCEMIA; IMMUNOCOMPETENT CELL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INTRACELLULAR SPACE; LYMPHOCYTE; MITOCHONDRION; MONOCYTE; NERVE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PERICYTE; PIGMENT DISORDER; PROPHYLAXIS; RETINA BLOOD VESSEL; SIGNAL TRANSDUCTION; VISUAL IMPAIRMENT;

DIABETIC RETINOPATHY; HUMANS; RISK FACTORS;

EID: 34250651740     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med 2005; 353: 839-841.
2. Ambati J, Chalam KV, Chawla DK et al. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1997; 115: 161-166.
3. Beltramo E, Buttiglieri S, Pomero F et al. A study of capillary pericyte viability on extracellular matrix produced by endothelial cells in high glucose. Diabetologia 2003; 46: 409-415.
4. Bendlová B (komentář k článku: Yang B, Cross DF, 2003. Polymorphism of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complications (české vydáníf) 2003; 1: 226-228.
5. Boehm BO, Lang G, Volpert O et al. Low content of the natural ocular antiangiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologia 2003; 46: 394-400.
6. Colhoun HM, Betteridge DJ, Durrington PN et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
7. DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N Eng J Med 1993; 329: 977-986.
8. Della Sala S, Bertoni G, Somazzi L et al. Impaired contrast sensitivity in diabetic patients with and without retinopathy: a new technique for rapid assessment. Br J Ophthalmol 1985; 69: 136-142.
9. Grant MB, Afzal A, Spoerri P et al. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 2004; 13: 1275-1293.
10. Grant MB, Caballero S jr. The potential role of octreotide in the treatment of diabetic retinopathy. Treat Endocrinol 2005; 4: 199-203.
11. Hammes HP. Pathophysiological mechanisms of diabetic angiopathy. J Diabetes Complications 2003; 17(2 Suppl): 16-19.
12. Hammes HP. Pericytes and the pathogenesis of diabetic retinopathy. Horm Metab Res 2005; 37(Suppl 1): 39-43.
13. Harada C, Mitamura Y, Harada T. The role of cytokines and trophic factors in epiretinal membranes: involvement of signal transduction in glial cells. Prog Retin Eye Res 2006; 25: 149-164.
14. Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31.
15. Chiarelli F, Giannini C, Di Marzio D et al. Treating diabetic retinopathy by tackling growth factor pathways. Curr Opin Investig Drugs 2005; 6: 395-409.
16. Isomaa B, Henricsson M, Almgren P et al. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001; 44: 1148-1154.
17. Joy SV, Scates AC, Bearelly S et al. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications. Ann Pharmacother 2005; 39: 1693-1699.
18. Kalvodová B, Sosna T, Řehák J et al. Standardy pro diagnostiku a léčbu diabetické retinopatie a jejích komplikací. Doporučení České diabetologické společnosti a České oftalmologické společnosti. Vnitř Lék 2003; 49: 314-318.
19. Keech A, Simes RJ, Barter P et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
20. Kim YH, Hong MK, Song JM et al. Diabetic retinopathy as a predictor of late clinical events following percutaneous coronary intervention. J Invasive Cardiol 2002; 14: 599-602.
21. Klein BE, Moss SE, Klein R et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 1991; 98: 1261-1265.
22. Klein R, Sharrett AR, Klein BE et al. ARIC Group. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study. Ophthalmology 2002; 109: 1225-1234.
23. Leal EC, Santiago AR, Ambrosio AF. Old and new drug targets in diabetic retinopathy: from biochemical changes to inflammation and neurodegeneration. Curr Drug Targets CNS Neurol Disord 2005;4:421-434.
24. Leiden HA, Dekker JM, Moll AC et al. Blood pressure, lipids, and obesity are associated with retinopathy. Diabetes Care 2002; 25: 1320-1325.
25. Li Q, Puro DG. Diabetes-induced dysfunction of the glutamate transporter in retinal Muller cells. Invest Ophthalmol Vis Sci 2002;43:3109-3116.
26. Lorenzi M, Gerhardinger C. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia 2001; 44: 791-804.
27. Maneschi F, Mashiter K, Kohner EM. Insulin resistance and insulin deficiency in diabetic retinopathy of non-insulin-dependent diabetes. Diabetes 1983; 32: 82-87.
28. Murata T, Hata Y, Ishibashi T et al. Response of experimental retinal neovascularization to thiazolidinediones. Arch Ophthalmol 2001; 119: 709-717.
29. Orchard TJ, Forrest KY, Kuller LH et al. Pittsburgh Epidemiology of Diabetes Complications Study. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2001; 24: 1053-1059.
30. Pelikánová T, Šimková R, Tesař V et al. Effect of acute hyperglycaemia on selected plasma and urinary cytokine antagonists in Type 1 diabetes mellitus. Diabetologia 2003; 46: 470-474.
31. Podesta F, Romeo G, Liu WH et al. Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitro. Am J Pathol 2000; 156: 1025-1032.
32. Porta M, Allione A. Current approaches and perspectives in the medical treatment of diabetic retinopathy. Pharmacol Ther 2004; 103: 167-177.
33. Porta M, Bandello F. Diabetic retinopathy. A clinical update. Diabetologia 2002; 45: 1617-1634.
34. Porta M, Sjoelie AK, Chaturvedi N et al. EURODIAB Prospective Complications Study Group. Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 2001; 44: 2203-2209.
35. Rogers MS, D'Amato RJ. The effect of genetic diversity on angiogenesis. Exp Cell Res 2006; 312: 561-574.
36. Singleton JR, Smith AG, Russell JW et al. Microvascular complications of impaired glucose tolerance. Diabetes 2003; 52: 2867-2873.
37. Sjolie AK, Moller F. Medical management of diabetic retinopathy. Diabet Med 2004; 21: 666-672.
38. Škrha J. Patogeneze vaskulárních komplikací diabetu. In: Bartoš V, Pelikánová T (eds). Praktická diabetologie. 3. ed. Praha: Maxdorf 2003: 211-218.
39. Terasaki H, Hirose H, Miyake Y. S-cone pathway sensitivity in diabetes measured with threshold versus intensity curves on flashed backgrounds. Invest Ophthalmol Vis Sci 1996; 37: 680-684.
40. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
41. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
42. Van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005; 293: 1509-1513.
43. Wilkinson-Berka JL. Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol 2006; 38: 752-765.